



## Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations

Keiji Nogami<sup>1</sup> · Midori Shima<sup>1</sup> · Katsuyuki Fukutake<sup>2</sup> · Teruhisa Fujii<sup>3</sup> · Masashi Taki<sup>4</sup> · Tadashi Matsushita<sup>5</sup> · Satoshi Higasa<sup>6</sup> · Tetsuji Sato<sup>7</sup> · Michio Sakai<sup>8</sup> · Morio Arai<sup>9</sup> · Haruhiko Uchikawa<sup>10</sup> · Werner Engl<sup>11</sup> · Brigitt Abbuehl<sup>11</sup> · Barbara A. Konkle<sup>12</sup>

Published online: 17 November 2017  
© The Japanese Society of Hematology 2017

**Correction to: Int J Hematol (2017) 106:704–710**  
<https://doi.org/10.1007/s12185-017-2265-6>

The authors would like to correct the error in Table 2 in the original publication of the article. The “Blood type” is not described in any part of “Results” and “Discussion” and had no impact on the conclusion hence the bottom of the table is removed.

The revised Table 2 is given in the following page for your reading.

---

The original article can be found online at <https://doi.org/10.1007/s12185-017-2265-6>.

---

✉ Keiji Nogami  
[roc-noga@naramed-u.ac.jp](mailto:roc-noga@naramed-u.ac.jp)

<sup>1</sup> Department of Pediatrics, Nara Medical University, Kashihara, Japan

<sup>2</sup> Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan

<sup>3</sup> Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan

<sup>4</sup> Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan

<sup>5</sup> Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan

<sup>6</sup> Division of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan

<sup>7</sup> Department of Pediatrics, University of Occupational and Environmental Health, Kitakyushu, Japan

<sup>8</sup> Department of Pediatrics, Munakata Suikokai General Hospital, Fukutsu, Japan

<sup>9</sup> Department of Medical Affairs, Baxalta Japan Ltd., Tokyo, Japan

<sup>10</sup> Department of Clinical Development Operations, Baxalta Japan Ltd., Tokyo, Japan

<sup>11</sup> Shire, Vienna, Austria

<sup>12</sup> Puget Sound Blood Center, University of Washington School of Medicine, Seattle, USA

**Table 2** Patient background data for subjects in Japan ( $N = 11$ )

No.	Age (years)	Weight (kg)	Previous treatment	Number of target joints at screening	Arthropathy at screening
1	30	57.1	Prophylaxis	0	Yes
2	47	67.8	Prophylaxis	0	Yes
3	24	65.9	Prophylaxis	1	Yes
4	47	66.6	Prophylaxis	1	Yes
5	29	88.0	Prophylaxis	5	Yes
6	49	70.1	Prophylaxis	3	Yes
7	19	73.0	Prophylaxis	0	Yes
8	22	51.8	Prophylaxis	1	Yes
9	50	76.0	Prophylaxis	0	Yes
10	34	61.8	Prophylaxis	4	Yes
11	25	66.3	Prophylaxis	0	Yes
Mean	34.2	67.7	N/A	1.4	N/A
Range	19–50	51.8–88.0	N/A	0–5	N/A

*ABR* annualized bleeding rate, *N/A* not applicable